Black Diamond Therapeutics (NASDAQ: BDTX) has appointed Fang Ni to serve as its chief business officer. Ni has held the role on an interim basis since the company emerged from stealth in late 2018.
Ni was most recently a principal and member of the investment team at Versant Ventures, which incubated Black Diamond before launching it with $20 million in Series A financing. During his time at Versant Ni also served as interim CBO for other emerging companies, including Monte Rosa Therapeutics and Bright Peak Therapeutics. Prior to Versant he was a business development and licensing director at Roche…. Read more »
UNDERWRITERS AND PARTNERS
